The purpose of our study was to determine the synergistic protective effects of mitochondria-targeted antioxidant SS31 and mitochondria division inhibitor 1 (Mdivi1) in Alzheimer’s disease (AD). Using biochemical methods, we assessed mitochondrial function by measuring the levels of hydrogen peroxide, lipid peroxidation, cytochrome c oxidase activity, mitochondrial ATP, and GTPase Drp1 enzymatic activity in mutant AβPP cells. Using biochemical methods, we also measured cell survival and apoptotic cell death. Amyloid-β (Aβ) levels were measured using sandwich ELISA, and using real-time quantitative RT-PCR, we assessed mtDNA (mtDNA) copy number in relation to nuclear DNA (nDNA) in all groups of cells. We found significantly reduced levels of Aβ40 and Aβ42 in mutant AβPP cells treated with SS31, Mdivi1, and SS31+Mdivi1, and the reduction of Aβ42 levels were much higher in SS31+Mdivi1 treated cells than individual treatments of SS31 and Mdivi1. The levels of mtDNA copy number and cell survival were significantly increased in SS31, Mdivi1, and SS31+Mdivi1 treated mutant AβPP cells; however, the increased levels of mtDNA copy number and cell survival were much higher in SS31+Mdivi1 treated cells than individual treatments of SS31 and Mdivi1. Mitochondrial dysfunction is significantly reduced in SS31, Mdivi1, and SS31+Mdivi1 treated mutant AβPP cells; however, the reduction is much higher in cells treated with both SS31+Mdvi1. Similarly, GTPase Drp1 activity is reduced in all treatments, but reduced much higher in SS31+Mdivi1 treated cells. These observations strongly suggest that combined treatment of SS31+Mdivi1 is effective than individual treatments of SS31 and Mdivi1. Therefore, we propose that combined treatment of SS31+Mdivi1 is a better therapeutic strategy for AD. Ours is the first study to investigate combined treatment of mitochondria-targeted antioxidant SS31 and mitochondrial division inhibitor 1 in AD neurons.
SwerdlowRH (2007) Pathogenesis of Alzheimer’s disease. Clin Interv Aging2, 347–359.
4.
MattsonMP (2004) Pathways towards and away from Alzheimer’s disease. Nature430, 631–639.
5.
ReddyPH, BealMF (2008) Amyloid beta, mitochondrial dysfunction and synaptic damage: Implications for cognitive decline in aging and Alzheimer’s disease. Trends Mol Med14, 45–53.
6.
DuH, GuoL, YanS, SosunovAA, McKhannGM, YanSS (2010) Early deficits in synaptic mitochondria in an Alzheimer’s disease mouse model. Proc Natl Acad Sci U S A107, 18670–18675.
7.
ReddyPH, TripathiR, TroungQ, TirumalaK, ReddyTP, AnekondaV, ShirendebUP, CalkinsMJ, ReddyAP, MaoP, ManczakM (2012) Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer’s disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochim Biophys Acta1822, 639–649.
8.
ZhuX, PerryG, SmithMA, WangX (2013) Abnormal mitochondrial dynamics in the pathogenesis of Alzheimer’s disease. J Alzheimers Dis33, S253–262.
DeviL, PrabhuBM, GalatiDF, AvadhaniNG, AnandatheerthavaradaHK (2006) Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer’s disease brain is associated with mitochondrial dysfunction. J Neurosci26, 9057–9068.
MaurerI, ZierzS, MöllerHJ (2000) A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging21, 455–462.
13.
ReddyPH, McWeeneyS, ParkBS, ManczakM, GutalaRV, PartoviD, JungY, YauV, SearlesR, MoriM, QuinnJ (2004) Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer’s disease. Hum Mol Genet13, 1225–1240.
14.
TrushinaE, NemutluE, ZhangS, ChristensenT, CampJ, MesaJ, SiddiquiA, TamuraY, SesakiH, WengenackTM, DzejaPP, PodusloJF (2012) Defects in mitochondrial dynamics and metabolomic signatures of evolving energetic stress in mouse models of familial Alzheimer’s disease. PLoS One7, e32737.
15.
ManczakM, AnekondaTS, HensonE, ParkBS, QuinnJ, ReddyPH (2006) Mitochondria are a direct site of A beta accumulation in Alzheimer’s disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet15, 1437–1449.
EckertA, HauptmannS, ScherpingI, RheinV, Müller-SpahnF, GötzJ, MüllerWE (2008) Soluble beta-amyloid leads to mitochondrial defects in amyloid precursor protein and tau transgenic mice. Neurodegener Dis5, 157–159.
18.
RheinV, SongX, WiesnerA, IttnerLM, BaysangG, MeierF, OzmenL, BluethmannH, DröseS, BrandtU, SavaskanE, CzechC, GötzJ, EckertA (2009) Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer’s disease mice. Proc Natl Acad Sci U S A106, 20057–20062.
19.
SmithMA, HiraiK, HsiaoK, PappollaMA, HarrisPL, SiedlakSL, TabatonM, PerryG (1998) Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem70, 2212–1215.
20.
PraticòD, UryuK, LeightS, TrojanoswkiJQ, LeeVM (2001) Increased lipid peroxidation precedes amyloid plaque formation in an animal model of Alzheimer amyloidosis. J Neurosci21, 4183–4137.
21.
DeviL, OhnoM (2013) Deletion of the eIF2α Kinase GCN2 fails to rescue the memory decline associated with Alzheimer’s disease. PLoS One8, e77335.
ManczakM, CalkinsMJ, ReddyPH (2011) Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer’s disease: Implications for neuronal damage. Hum Mol Genet20, 2495–2509.
24.
CalkinsMJ, ManczakM, MaoP, ShirendebU, ReddyPH (2011) Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer’s disease. Hum Mol Genet20, 4515–4529.
25.
WangX, SuB, SiedlakSL, MoreiraPI, FujiokaH, WangY, CasadesusG, ZhuX (2008) Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci U S A105, 19318–19323.
26.
WangX, SuB, LeeHG, LiX, PerryG, SmithMA, ZhuX (2009) Impaired balance of mitochondrial fission and fusion in Alzheimer’s disease. J Neurosci29, 9090–9103.
27.
CaspersenC, WangN, YaoJ, SosunovA, ChenX, LustbaderJW, XuHW, SternD, McKhannG, YanSD (2005) Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer’s disease. FASEB J19, 2040–2041.
28.
CrouchPJ, BlakeR, DuceJA, CiccotostoGD, LiQX, BarnhamKJ, CurtainCC, ChernyRA, CappaiR, DyrksT, MastersCL, TrounceIA (2005) Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci25, 672–679.
29.
YaoJ, IrwinRW, ZhaoL, NilsenJ, HamiltonRT, BrintonRD (2009) Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A106, 14670–14675.
30.
Hansson PetersenCA, AlikhaniN, BehbahaniH, WiehagerB, PavlovPF, AlafuzoffI, LeinonenV, ItoA, WinbladB, GlaserE, AnkarcronaM (2008) The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci U S A105, 13145–13150.
MurphyMP, SmithRA (2007) Targeting antioxidants to mitochondria by conjugation to lipophilic cations. Annu Rev Pharmacol Toxicol47, 629–656.
33.
ZhaoGM, QianX, SchillerPW, SzetoHH (2003) Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors. J Pharmacol Exp Ther307, 947–954.
PetriS, KiaeiM, DamianoM, HillerA, WilleE, ManfrediG, CalingasanNY, SzetoHH, BealMF (2006) Cell-permeable peptide antioxidants as a novel therapeutic approach in a mouse model of amyotrophic lateral sclerosis. J Neurochem98, 1141–1148.
38.
Cassidy-StoneA, ChipukJE, IngermanE, SongC, YooC, KuwanaT, KurthMJ, ShawJT, HinshawJE, GreenDR, NunnariJ (2008) Chemical inhibition of the mitochondrial division dynamin reveals its role in Bax/Bak-dependent mitochondrial outer membrane permeabilization. Dev Cell14, 193–204.
39.
MaciaE, EhrlichM, MassolR, BoucrotE, BrunnerC, KirchhausenT (2006) Dynasore, a cell-permeable inhibitor of dynamin. Dev Cell10, 839–850.
40.
QiX, QvitN, SuYC, Mochly-RosenD (2013) A novel Drp1 inhibitor diminishes aberrant mitochondrial fission and neurotoxicity. J Cell Sci126, 789–802.
41.
XieN, WangC, WuC, ChengX, GaoY, ZhangH, ZhangY, LianY (2016) Mdivi-1 protects epileptic hippocampal neurons from apoptosis via inhibiting oxidative stress and endoplasmic reticulum stress in vitro. Neurochem Res41, 1335–1342.
42.
QiuX, CaoL, YangX, ZhaoX, LiuX, HanY, XueY, JiangH, ChiZ (2013) Role of mitochondrial fission in neuronal injury in pilocarpine-induced epileptic rats. Neuroscience245, 157–165.
43.
OngSB, SubrayanS, LimSY, YellonDM, DavidsonSM, HausenloyDJ (2010) Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation121, 2012–2022.
ParkSW, KimKY, LindseyJD, DaiY, HeoH, NguyenDH, EllismanMH, WeinrebRN, JuWK (2011) A selective inhibitor of drp1, mdivi-1, increases retinal ganglion cell survival in acute ischemic mouse retina. Invest Ophthalmol Vis Sci52, 2837–2843.
46.
WapplerEA, InstitorisA, DuttaS, KatakamPV, BusijaDW (2013) Mitochondrial dynamics associated with oxygen-glucose deprivation in rat primary neuronal cultures. PLoS One8, e63206.
47.
ReddyPH, ManczakM, YinX (2017) Mitochondria-division inhibitor 1 protects against amyloid-β induced mitochondrial fragmentation and synaptic damage in Alzheimer’s disease. J Alzheimers Dis58, 147–162.
48.
ManczakM, KandimallaR, FryD, SesakiH, ReddyPH (2016) Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease. Hum Mol Genet25, 5148–5166.
49.
ReddyPH, ManczakM, YinX, GradyMC, MitchellA, KandimallaR, KuruvaCS (2016) Protective effects of a natural product, curcumin, against amyloid β induced mitochondrial and synaptic toxicities in Alzheimer’s disease. J Investig Med64, 1220–1234.
50.
ManczakM, ReddyPH (2012) Abnormal interaction between the mitochondrial fission protein Drp1 and hyperphosphorylated tau in Alzheimer’s disease neurons: Implications for mitochondrial dysfunction and neuronal damage. Hum Mol Genet21, 2538–2547.
51.
ManczakM, ReddyPH (2015) Mitochondrial division inhibitor 1 protects against mutant huntingtin-induced abnormal mitochondrial dynamics and neuronal damage in Huntington’s disease. Hum Mol Genet24, 7308–7325.
52.
ReddyPH, ManczakM, KandimallaR (2017) Mitochondria-targeted small molecule SS31: A potential candidate for the treatment of Alzheimer’s disease. Hum Mol Genet26, 1483–1496.
53.
WangW, YinJ, MaX, ZhaoF, SiedlakSL, WangZ, FujiokaH, XuY, PerryG and ZhuX (2017) Inhibition of mitochondrial fragmentation protects against Alzheimer’s disease in rodent model. Hum Mol Genet26, 4118–4131.
GourasGK, TsaiJ, NaslundJ, VincentB, EdgarM, CheclerF, GreenfieldJP, HaroutunianV, BuxbaumJD, XuH, GreengardP, RelkinNR (2000) Intraneuronal Abeta42 accumulation in human brain. Am J Pathol156, 15–20.
56.
GourasGK, AlmeidaCG, TakahashiRH (2005) Intraneuronal Abeta accumulation and origin of plaques in Alzheimer’s disease. Neurobiol Aging26, 1235–1244.
57.
TakahashiRH, NagaoT, GourasGK (2017) Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer’s disease. Pathol Int67, 185–193.
58.
MaoP, ManczakM, CalkinsMJ, TruongQ, ReddyTP, ReddyAP, ShirendebU, LoHH, RabinovitchPS, ReddyPH (2012) Mitochondria-targeted catalase reduces abnormal APP processing, amyloid β production and BACE1 in a mouse model of Alzheimer’ disease: Implications for neuroprotection and lifespan extension. Hum Mol Genet21, 2973–2990.
